J9352 HCPCS Level II code: Injection, trabectedin, 0.1 mg
CMS terminated J9352: its last date of service was Sep 30, 2026. It stays here for looking up older claims; newer services need a current code.
Official description
J9352Injection, trabectedin, 0.1 mg
Short description: Injection trabectedin 0.1mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J9352 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Chemotherapy
- Added
- Jan 1, 2017
- Terminated after
- Sep 30, 2026
Where J9352 sits
- 1J codesDrugs administered other than orally
- 2Terminated J9352Injection, trabectedin, 0.1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code J9352 still valid?
No. CMS terminated J9352; its last date of service was Sep 30, 2026. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover J9352?
CMS lists J9352’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9352
All J codesJ9345Injection, retifanlimab-dlwr, 1 mgJ9347Injection, tremelimumab-actl, 1 mgJ9348Injection, naxitamab-gqgk, 1 mgJ9349Injection, tafasitamab-cxix, 2 mgJ9350Injection, mosunetuzumab-axgb, 1 mgJ9351Injection, topotecan, 0.1 mgJ9353Injection, margetuximab-cmkb, 5 mgJ9354Injection, ado-trastuzumab emtansine, 1 mgJ9355Injection, trastuzumab, excludes biosimilar, 10 mgJ9356Injection, trastuzumab, 10 mg and hyaluronidase-oyskJ9357Injection, valrubicin, intravesical, 200 mgJ9358Injection, fam-trastuzumab deruxtecan-nxki, 1 mg